Hillevax

Hillevax Div.-Adj. PEG

Delisted

Dividend-Adjusted PEG Ratio of Hillevax (HLVX) as of Nov 20, 2026.

Div.-Adj. PEG

-

Last updated:

Dividend-Adjusted PEG Ratio of Hillevax is 2026 - . Dividend-Adjusted PEG Ratio of Hillevax was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hillevax Stock analysis

What does Hillevax do? HilleVax, Inc. develops and commercializes novel vaccines, focusing on HIL-214, a bivalent virus-like particle (VLP) vaccine candidate for norovirus-induced acute gastroenteritis. The vaccine combines VLPs for norovirus genotypes GI.1 and GII.4 with an aluminum hydroxide adjuvant to enhance immune response. HIL-214 targets moderate-to-severe cases of norovirus infection, which causes symptoms like diarrhea, vomiting, and dehydration. The company's primary revenue stream will come from the future commercialization of HIL-214 after regulatory approval, with potential sales to healthcare providers and public health programs. Hillevax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hillevax stock

On Eulerpool you can find the complete historical development of Dividend-Adjusted PEG Ratio Hillevax since 2006 – with annual values, charts, and detailed analysis.

The dividend-adjusted PEG ratio factors in dividend yield alongside earnings growth, providing a more complete valuation for income-paying stocks.

To evaluate Dividend-Adjusted PEG Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Dividend-Adjusted PEG Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Dividend-Adjusted PEG Ratio's Hillevax with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Hillevax

All Key Metrics — Hillevax